Mount Sinai’s multifaceted research portfolio reflects its unwavering commitment to confronting some of oncology’s most challenging frontiers. This year’s presentations span a diverse spectrum of cancer specialties, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, translational science, and cancer care delivery. The breadth and depth of these contributions underscore Mount Sinai’s role as a leader in developing sophisticated, personalized approaches to cancer therapy—approaches that marry benchside discoveries with bedside applications.

Among the highlights is a highly anticipated late-breaking oral presentation by Dr. John Mascarenhas, Professor of Medicine and Director of the Center of Excellence for Blood Cancer and Myeloid Disorders at Mount Sinai Tisch Cancer Center. Dr. Mascarenhas will reveal pivotal results from the phase 3 SENTRY trial, which evaluates the combination of selinexor and ruxolitinib in patients with JAK inhibitor-naïve myelofibrosis. This trial explores a novel therapeutic strategy designed to inhibit aberrant signaling pathways responsible for the proliferation of malignant hematopoietic cells. Scheduled for June 2 during the Hematologic Malignancies oral abstract session, these findings hold significant promise for patients with this debilitating myeloproliferative disorder.

In the arena of thoracic oncology, Mount Sinai investigators are advancing the frontier of immunotherapy through research on HLX43, an anti-PD-L1 antibody-drug conjugate. This Rapid Oral Abstract Session presentation examines HLX43’s efficacy and safety in patients with advanced non-small cell lung cancer (NSCLC), delving into its potential to harness immune checkpoint inhibition to augment tumor targeting and destruction. Antibody-drug conjugates represent a cutting-edge modality designed to deliver cytotoxic agents directly to cancer cells while minimizing off-target effects.

Beyond these oral sessions, Mount Sinai’s robust research pipeline includes a variety of poster presentations tackling pressing questions across multiple cancer types. Studies investigating macrophage polarization in metastatic urothelial cancer highlight the CXCL9:SPP1 ratio as a predictive biomarker for response to pembrolizumab and enfortumab vedotin combination therapies. This work provides new insights into tumor microenvironment dynamics, emphasizing the role of immune cell modulation in therapeutic outcomes.

Additional poster research assesses national trends in immunotherapy use among patients with metastatic head and neck squamous cell carcinoma, employing data from the National Cancer Database. These epidemiological studies reveal critical patterns in end-of-life treatment, ultimately guiding more compassionate and effective care strategies. Further work from Mount Sinai evaluates overall survival patterns in mucosal melanoma patients before and after the widespread adoption of PD-1 based checkpoint inhibitors, shedding light on the transformative impact of immunotherapy in rare and aggressive malignancies.

Investigations into relapsed/refractory multiple myeloma feature comparative analyses of belantamab mafodotin added to bortezomib and dexamethasone versus standard of care. These studies are instrumental in refining therapeutic algorithms and optimizing patient outcomes in a disease known for its complexity and heterogeneity. On the biomarker frontier, research on Keratin 19 (KRT19) as a circulating tumor biomarker offers a promising avenue for non-invasive disease monitoring and treatment guidance in urothelial carcinoma.

Cutting-edge molecular diagnostics are also exemplified by studies evaluating pre-cystectomy circulating tumor DNA (ctDNA) levels to differentiate patients with surgically curable disease from those harboring occult micrometastatic progression. These advances could pave the way for precision staging and personalized adjuvant therapy strategies, revolutionizing bladder cancer management.

Mount Sinai clinicians continue to pioneer novel immunomodulatory therapeutic concepts, such as trials investigating tolododekin alfa (ANK-101) in combination with anti-PD-1/PD-L1 antibodies in advanced NSCLC. This phase 1b study aims to potentiate immune responses by modulating cytokine environments, potentially overcoming resistance mechanisms inherent to checkpoint blockade monotherapy.

Urothelial carcinoma research remains a central focus, exemplified by multiple studies including the CheckMate-901 trial examining biomarker profiles associated with durable disease control in advanced disease treated with nivolumab plus ipilimumab. Similarly, the TROPION-Urothelial03 trial compares datopotamab deruxtecan plus chemotherapy versus the current standard of care in heavily pretreated patients, illustrating Mount Sinai’s commitment to improving outcomes in this challenging cancer subtype.

In the realm of myelofibrosis, the MY-PAC study investigates treatment patterns and clinical outcomes among patients treated with pacritinib, especially those with higher platelet counts. This research helps elucidate safety and efficacy profiles critical to managing this patient population. Additionally, updates on IMPROVEMF, a phase 1b trial combining imetelstat and ruxolitinib in intermediate and high-risk myelofibrosis, signify ongoing efforts to enhance therapeutic benefits and address unmet clinical needs.

The Mount Sinai Tisch Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, remains at the forefront of integrating basic, clinical, and population health research. With a strategic focus on tumor types prevalent in its catchment area—including liver, prostate, breast, bladder, and lung cancers—Mount Sinai is uniquely positioned to translate cutting-edge research into meaningful advancements in patient care. Its extensive network, encompassing seven hospitals and over 400 physician practices, allows Mount Sinai to deliver multidisciplinary expertise alongside a growing portfolio of innovative clinical trials.

Notably, the construction of the soon-to-be-completed Mount Sinai Tisch Cancer Hospital will further augment the center’s capacity for pioneering research and patient-centered care, equipped with state-of-the-art facilities designed to accelerate translational research and clinical innovation. As these advancements unfold, Mount Sinai continues to steer oncology toward a future where personalized medicine transforms prognosis and quality of life for patients worldwide.

For more information about the ASCO Annual Meeting and to explore the full breadth of research presented by Mount Sinai, visit the official ASCO Annual Meeting website.

Subject of Research: Cancer research, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, immunotherapy, biomarker-driven approaches, multiple myeloma, and myelofibrosis.

Article Title: Mount Sinai Tisch Cancer Center Unveils Breakthrough Cancer Research at ASCO 2026 Annual Meeting

News Publication Date: May 27, 2026

Web References:

• https://www.asco.org/annual-meeting
• https://www.asco.org/abstracts-presentations/262643
• https://www.asco.org/abstracts-presentations/263356
• https://www.asco.org/abstracts-presentations/261730
• https://www.asco.org/abstracts-presentations/267968
• https://www.asco.org/abstracts-presentations/260701
• https://www.asco.org/abstracts-presentations/262647
• https://www.asco.org/abstracts-presentations/266782
• https://www.asco.org/abstracts-presentations/262606
• https://www.asco.org/abstracts-presentations/266904
• https://www.asco.org/abstracts-presentations/267846
• https://www.asco.org/abstracts-presentations/266659

Keywords: Myelofibrosis, hematologic malignancies, antibody-drug conjugates, immunotherapy, non-small cell lung cancer, urothelial carcinoma, circulating tumor DNA, biomarker-driven treatment, multiple myeloma, PD-1 checkpoint inhibitors, cancer clinical trials, personalized cancer therapy.

Traditional screening approaches for endometrial cancer predominantly revolve around the identification of clinical symptoms such as abnormal vaginal bleeding and the use of imaging modalities like transvaginal ultrasound (TVU). Although vaginal bleeding is considered a hallmark symptom, its diagnostic utility is undermined by its nonspecific nature, as bleeding often overlaps with benign gynecologic conditions, contributing to diagnostic ambiguity and potential delays. TVU, despite its widespread clinical application, exhibits moderate specificity with approximately 60–70%, and while its sensitivity ranges between 80–90%, a significant 35% of early-stage or hormone-independent Type II tumors elude detection, thus perpetuating diagnostic gaps.

In parallel, serum tumor markers including CA125 and Human Epididymis Protein 4 (HE4) have been explored as minimally invasive tools for screening, yet their effectiveness is predominantly confined to advanced disease settings. Both markers lack sufficient sensitivity and specificity for early detection; HE4’s utility is further complicated by heterogeneous study results that reflect variable biomarker expression across patient populations. As a consequence, reliance on these markers alone does not suffice to transform early diagnostic paradigms.

Histopathological evaluation remains the gold standard diagnostic criterion, offering definitive tumor characterization and staging. However, it necessitates invasive sampling procedures that carry procedural risks and often deter patient compliance. Novel cytological sampling devices such as Pipelle and Tao Brush have emerged to facilitate outpatient endometrial cell collection, yet these techniques face inherent challenges in capturing focal neoplastic lesions, limiting sensitivity. This trade-off between diagnostic accuracy and procedural invasiveness accentuates the need for innovative, non-invasive, and reliable screening alternatives.

Recent advances in molecular diagnostics are ushering a paradigm shift in endometrial cancer screening, predicated on the detection of specific genetic and epigenetic alterations in easily accessible biological samples. DNA methylation panels targeting genes like ADCYAP1 and HAND2 have demonstrated compelling performance in phase II clinical trials, with sensitivities ranging from 89% to 94% and specificities between 91% and 97% when applied in liquid biopsies. These markers offer the ability to detect epigenetic silencing events characteristic of early tumorigenesis, enabling non-invasive detection and longitudinal monitoring, particularly for high-risk cohorts such as individuals with Lynch syndrome.

Genomic profiling strategies further complement epigenetic approaches by detecting somatic and germline mutations in pivotal tumor suppressor and chromatin remodeling genes, including PTEN, TP53, and ARID1A. Sensitivities approaching 93% have been reported for hereditary EC identification, underscoring the potential application of personalized screening informed by genetic risk factors. Concurrently, the burgeoning field of exosomal microRNA analysis is providing novel biomarker avenues—circulating exosomal miR-15a-5p notably distinguishes patients with endometrial cancer, correlating with tumor invasiveness metrics such as myometrial infiltration, achieving an area under the curve (AUC) of 0.823, a promising indicator of diagnostic accuracy.

Liquid biopsy techniques, particularly those involving circulating tumor DNA (ctDNA), represent a frontier in minimally invasive cancer diagnostics. When synergized with tumor-educated platelet analyses, sensitivities for early-stage EC detection reach approximately 78%. Despite this promise, challenges persist in standardizing protocols, ensuring reproducibility, and mitigating high associated costs to facilitate broad clinical adoption.

Vibrational spectroscopy has emerged as an innovative modality capable of detecting biophysical and molecular alterations in tissue and blood samples. Operating through techniques like Raman and Fourier-transform infrared (FTIR) spectroscopy, these approaches consistently report sensitivities around 87% and specificities near 78%, offering rapid intraoperative diagnostic potential and supplementary screening utility beyond conventional histopathology.

Artificial intelligence (AI) is progressively reshaping endometrial cancer diagnostics by integrating complex datasets encompassing patient demographics, imaging findings, and molecular biomarker profiles. AI-enhanced risk prediction models, exemplified by adaptations of the Risk of Malignancy Index, report sensitivities nearing 94% and specificities around 75%, providing refined risk stratification that can guide clinical decision-making. Moreover, deep learning algorithms applied to cytological specimens have achieved positive predictive values of up to 95%, underscoring the transformative capacity of AI in automating and augmenting diagnostic workflows.

Effective implementation of these cutting-edge technologies necessitates rigorous risk stratification frameworks targeting high-risk groups such as women with obesity (BMI >30), diabetes, nulliparity, late menopause, and those harboring hereditary predispositions like Lynch syndrome. For these populations, current strategies recommend annual transvaginal ultrasounds combined with endometrial biopsies commencing between ages 30 and 35. Beyond diagnostics, therapeutic approaches for early-stage EC emphasize fertility preservation, leveraging progestins, levonorgestrel-releasing intrauterine devices, and gonadotropin-releasing hormone (GnRH) agonists, accompanied by close clinical surveillance to optimize reproductive outcomes without compromising oncologic safety.

Economic and ethical considerations intricately weave into the screening paradigm. Emerging evidence, including Nordic cost-effectiveness analyses, highlights that integrating AI and DNA methylation testing can curtail long-term healthcare expenditures by reducing reliance on invasive procedures by approximately 20% over five years. Ethical imperatives concurrently mandate minimizing patient exposure to invasive diagnostics, alleviating false-positive related anxieties, and ensuring equitable access across sociodemographic strata to avoid exacerbating healthcare disparities.

Looking ahead, the future trajectory of endometrial cancer screening hinges on large-scale, prospective validations of multimodal approaches that amalgamate DNA methylation panels, exosomal microRNAs, and AI-driven analytics in community settings. Such integrative frameworks promise enhanced sensitivity and specificity at the population level, streamlining early detection. Policy evolution to endorse risk-based screening models and subsidize high-accuracy molecular assays is vital to translating these innovations into routine clinical practice, driving global reductions in endometrial cancer mortality.

In conclusion, the landscape of endometrial cancer screening is undergoing a profound transformation. Moving beyond traditional symptom-dependent modalities, the integration of molecular biomarkers, AI-powered analytical platforms, and non-invasive technologies heralds a new era of precision oncology. These advances collectively promise to surmount longstanding diagnostic barriers, facilitating earlier detection, personalized risk assessment, and optimized management strategies, ultimately improving patient outcomes on a global scale.

Subject of Research: Endometrial Cancer Screening Innovations and Diagnostic Technologies

Article Title: Exploring the Current State and Research Innovation in Endometrial Cancer Screening

News Publication Date: 30-Mar-2025

Web References:
https://www.xiahepublishing.com/journal/oncoladv
http://dx.doi.org/10.14218/OnA.2024.00034

Keywords: Endometrial cancer, cancer screening, genomics, molecular biomarkers, AI-driven diagnostics, liquid biopsy, DNA methylation, exosomal microRNA, vibrational spectroscopy, risk stratification